JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB265302

Human MISP (C19orf21) knockout HeLa cell line

Be the first to review this product! Submit a review

|

(0 Publication)

MISP KO cell line available to order. KO validated. Free of charge wild type control available. Knockout achieved by using CRISPR/Cas9, 1 bp deletion in exon 2 and 1 bp insertion in exon 2. To order both knockout and wild-type control cells: select '2 x 1000000 Cells/vial'. To order only knockout cells: select '1000000 Cells/vial'.
2 Images
Sanger Sequencing - Human MISP (C19orf21) knockout HeLa cell line (AB265302)
  • Sanger seq

Unknown

Sanger Sequencing - Human MISP (C19orf21) knockout HeLa cell line (AB265302)

Allele-1 : 1 bp deletion in exon 2.

Sanger Sequencing - Human MISP (C19orf21) knockout HeLa cell line (AB265302)
  • Sanger seq

Unknown

Sanger Sequencing - Human MISP (C19orf21) knockout HeLa cell line (AB265302)

Allele-2 : 1 bp insertion in exon 2.

Key facts

Cell type

HeLa

Species or organism

Human

Tissue

Cervix

Form

Liquid

form

Knockout validation

Sanger Sequencing

Mutation description

Knockout achieved by using CRISPR/Cas9, 1 bp deletion in exon 2 and 1 bp insertion in exon 2

Disease

Adenocarcinoma

Product details

We will provide viable cells that proliferate on revival.

This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our limited use license and patent pages.

What's included?

{ "values": { "2x1000000Cellsvial": { "sellingSize": "2 x 1000000 Cells/vial", "publicAssetCode":"ab265302-2x1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab255928 Human wild-type HeLa cell line", "number":"AB265302-CMP02" }, { "size":"1 x 1000000 Cells/vial", "name":"ab265302 Human MISP (C19orf21) knockout HeLa cell line", "number":"AB265302-CMP01" } ] }, "2x1000000Cellsvial": { "sellingSize": "2 x 1000000 Cells/vial", "publicAssetCode":"ab265302-2x1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab255928 Human wild-type HeLa cell line", "number":"AB265302-CMP02" }, { "size":"1 x 1000000 Cells/vial", "name":"ab265302 Human MISP (C19orf21) knockout HeLa cell line", "number":"AB265302-CMP01" } ] }, "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab265302-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab265302 Human MISP (C19orf21) knockout HeLa cell line", "number":"AB265302-CMP01" } ] }, "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab265302-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab265302 Human MISP (C19orf21) knockout HeLa cell line", "number":"AB265302-CMP01", "productcode":"" } ] } } }

Properties and storage information

Gene name
MISP
Gene editing type
Knockout
Gene editing method
CRISPR technology
Knockout validation
Sanger Sequencing
Shipped at conditions
Dry Ice
Appropriate short-term storage conditions
-196°C
Appropriate long-term storage conditions
-196°C

Handling procedures

Initial handling guidelines

Upon arrival, the vial should be stored in liquid nitrogen vapor phase and not at -80°C. Storage at -80°C may result in loss of viability.

1. Thaw the vial in 37°C water bath for approximately 1-2 minutes.
2. Transfer the cell suspension (0.8 mL) to a 15 mL/50 mL conical sterile polypropylene centrifuge tube containing 8.4 mL pre-warmed culture medium, wash vial with an additional 0.8 mL culture medium (total volume 10 mL) to collect remaining cells, and centrifuge at 201 x g (rcf) for 5 minutes at room temperature. 10 mL represents minimum recommended dilution. 20 mL represents maximum recommended dilution.
3. Resuspend the cell pellet in 5 mL pre-warmed culture medium and count using a haemocytometer or alternative cell counting method seed all remaining cells into a T25.
4. Incubate the culture at 37°C incubator with 5% CO2. Check the culture one day after revival and continue to check until 80% confluent. Media change can be given if needed.
5. Once confluent passage into an appropriate flask at a density of 2x104 cells/cm2. Seeding density is given as a guide only and should be scaled to align with individual lab schedules. Cultures should be monitored daily.

Subculture guidelines
  • All seeding densities should be based on cell counts gained by established methods.
  • A guide seeding density of 2x104 cells/cm2 is recommended.
  • Cells should be passaged when they have achieved 80-90% confluence.
Culture medium

DMEM (High Glucose) + 10% FBS

Cryopreservation medium

Cell Freezing Medium-DMSO Serum free media, contains 8.7% DMSO in MEM supplemented with methyl cellulose.

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

C19orf21 also known as Chromosome 19 Open Reading Frame 21 is a protein with a molecular mass of approximately 26 kDa. It is expressed in various tissues with significant activity in the spleen and lung. Mechanically C19orf21 functions in nuclear processes including transcription regulation and chromatin remodeling. Due to its involvement in these activities C19orf21 interacts with nuclear components and may impact gene expression by influencing chromatin structure.
Biological function summary

C19orf21 plays a role in regulating cellular homeostasis and proliferation. C19orf21 is part of the chromatin remodeling complex which modifies chromatin to allow access to transcription machinery. This participation suggests importance in controlling gene accessibility. C19orf21's involvement in such intricate processes indicates a possible role in cellular development and differentiation influencing tissue-specific gene expression.

Pathways

C19orf21 is involved in chromatin modification and transcriptional regulation pathways. It interacts with proteins like histone acetyltransferases contributing to epigenetic modifications and regulation of gene expression. Additionally C19orf21 shows involvement in pathways that maintain DNA integrity working alongside proteins like DNA repair enzymes. These interactions suggest that C19orf21 supports cellular responses to damage and stress.

C19orf21 has been implicated in certain types of cancer and neurological disorders. In cancer it relates to transcription dysregulation potentially interacting with oncogenic factors. Aberrant expression or mutation of C19orf21 may disrupt normal gene regulation leading to tumorigenesis. In neurological disorders C19orf21's role in chromatin remodeling could affect gene expression patterns associated with neural function linking it to conditions such as Alzheimer's disease. In these contexts C19orf21 may interact with known proteins involved such as beta-amyloid precursor protein in Alzheimer's suggesting a wider implication in disease mechanisms.

Quality control

STR analysis

CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX

Cell culture

Biosafety level

EU: 2 US: 2

Adherent/suspension

Adherent

Gender

Female

Product protocols

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com